Skip to main navigation Skip to search Skip to main content

Cluster analysis and prediction of treatment outcomes for chronic rhinosinusitis

  • Zachary M. Soler
  • , J. Madison Hyer
  • , Luke Rudmik
  • , Viswanathan Ramakrishnan
  • , Timothy L. Smith
  • , Rodney J. Schlosser

Research output: Contribution to journalArticlepeer-review

Abstract

Background Current clinical classifications of chronic rhinosinusitis (CRS) have weak prognostic utility regarding treatment outcomes. Simplified discriminant analysis based on unsupervised clustering has identified novel phenotypic subgroups of CRS, but prognostic utility is unknown. Objective We sought to determine whether discriminant analysis allows prognostication in patients choosing surgery versus continued medical management. Methods A multi-institutional prospective study of patients with CRS in whom initial medical therapy failed who then self-selected continued medical management or surgical treatment was used to separate patients into 5 clusters based on a previously described discriminant analysis using total Sino-Nasal Outcome Test-22 (SNOT-22) score, age, and missed productivity. Patients completed the SNOT-22 at baseline and for 18 months of follow-up. Baseline demographic and objective measures included olfactory testing, computed tomography, and endoscopy scoring. SNOT-22 outcomes for surgical versus continued medical treatment were compared across clusters. Results Data were available on 690 patients. Baseline differences in demographics, comorbidities, objective disease measures, and patient-reported outcomes were similar to previous clustering reports. Three of 5 clusters identified by means of discriminant analysis had improved SNOT-22 outcomes with surgical intervention when compared with continued medical management (surgery was a mean of 21.2 points better across these 3 clusters at 6 months, P <.05). These differences were sustained at 18 months of follow-up. Two of 5 clusters had similar outcomes when comparing surgery with continued medical management. Conclusion A simplified discriminant analysis based on 3 common clinical variables is able to cluster patients and provide prognostic information regarding surgical treatment versus continued medical management in patients with CRS.

Original languageEnglish (US)
Pages (from-to)1054-1062
Number of pages9
JournalJournal of Allergy and Clinical Immunology
Volume137
Issue number4
DOIs
StatePublished - Apr 1 2016

Funding

Z.M.S. and T.L.S. were supported for this investigation by a grant from the National Institute on Deafness and Other Communication Disorders (NIDCD), one of the National Institutes of Health, Bethesda, Maryland (R01 DC005805; PI/PD: T.L.S.). Public clinical trial registration (http://www.clinicaltrials.gov) was #NCT01332136. Z.M.S. was also supported for this investigation by another grant from the NIDCD (R03 DC013651-01). T.L.S. is a consultant for IntersectENT, which is not associated with this manuscript. Z.M.S. is a consultant for Olympus, which is not affiliated with this manuscript. R.J.S. is supported by grants from OptiNose and IntersectENT, neither of which are associated with this manuscript. R.J.S. is also a consultant for Olympus and Arrinex, which are not affiliated with this study. Z.M.S. and T.L.S. were supported for this investigation by a grant from the National Institute on Deafness and Other Communication Disorders (NIDCD), one of the National Institutes of Health , Bethesda, Maryland ( R01 DC005805 ; PI/PD: T.L.S.). Public clinical trial registration ( http://www.clinicaltrials.gov ) was # NCT01332136 . Z.M.S. was also supported for this investigation by another grant from the NIDCD ( R03 DC013651-01 ). T.L.S. is a consultant for IntersectENT, which is not associated with this manuscript. Z.M.S. is a consultant for Olympus, which is not affiliated with this manuscript. R.J.S. is supported by grants from OptiNose and IntersectENT, neither of which are associated with this manuscript. R.J.S. is also a consultant for Olympus and Arrinex, which are not affiliated with this study.

FundersFunder number
OptiNose
Author National Institutes of Health National Institutes of Health National Institutes of Health National Institutes of Health The Bev Hartig Huntington's Disease Foundation National Institutes of Health01332136, R03 DC013651-01, UL1TR001450
National Institute on Deafness and Other Communication Disorders R01DC012546 Xue Zhong Liu National Institute on Deafness and Other Communication Disorders R01DC012115 Xue Zhong Liu National Institute on Deafness and Other Communication Disorders R01DC014427 Ulrich Müller Peter G Barr-Gillespie National Institute on Deafnessand Other Communication Disorders R01DC005965 Ulrich Müller National Institute on Deafness and Other Communication DisordersR01DC005805
Olympus ACMI

    Keywords

    • Chronic rhinosinusitis
    • cluster
    • outcomes
    • prediction
    • quality of life
    • sinusitis
    • treatment

    ASJC Scopus subject areas

    • Immunology and Allergy
    • Immunology

    Fingerprint

    Dive into the research topics of 'Cluster analysis and prediction of treatment outcomes for chronic rhinosinusitis'. Together they form a unique fingerprint.

    Cite this